ABSTRACT
Introduction
Prognosis for patients with recurrent glioblastoma (GBM) is dismal with a median survival of 3 -6 months [1] . Factors that contribute to GBM recurrence include its infiltrative nature in the brain tissue which limits the effectiveness of complete surgical resection; presence of residual hypoxic tumor cells that are relatively resistant to radio and chemotherapy [2] and the blood-brain barrier (BBB) that restrains access of systemically administered therapy [3] .
Current therapeutic strategies for patients with brain tumors are based on histological analysis which is insufficient for classification and grading of gliomas considering the molecular heterogeneity. Histological features vary from large ischemic and necrotic areas with intense angiogenesis frequently observed in primary glioblastoma, to a minor fraction presenting foci of oligodendroglioma-like tumor cell differentiation [4] [5] [6] GBM may develop de novo (primary GBM) or through progression from low-grade astrocytoma (secondary GBM) indicating that it has evolved through different genetic pathways and probably differ in prognosis and response to therapy [5, 7] Main genetic alterations of primary GBM include loss of heterozygosity 10q (70% of cases), EGFR amplification (36%), p16INK4a deletion (31%), and PTEN mutations (25%). In the pathway to secondary glioblastoma, TP53 mutations at CpG sites are the most frequent and earliest detectable genetic alteration already present in 60% of precursor low-grade astrocytoma. Yet, loss of heterozygosity 10q25-qter (70%) is a frequent alteration common to both primary and secondary glioblastoma [7] .
Activation of phosphatidylinositol-3-kinase (P13K/Akt) and Ras/MAPK pathways contributes to the malignant phenotype by disrupting cell cycle, increasing cell migration, enhancing cell survival and promoting angiogenesis [8] [9] [10] . Ras proteins, a family of small guanine nucleotide binding proteins involved in cellular signal transduction undergo several postranslational modifications that facilitate its attachment to the inner surface of the plasma membrane [11] . The first and most critical Ras modification to the biological active form is the addition of a farnesyl isoprenoid moiety in a reaction catalyzed by the enzyme farnesyltransferase (FTase) [12] . Anti-Ras pharmacyologic inhibitors under clinical evaluation include drugs able to prevent 1) association with the plasma membrane (prenylation and post prenylation inhibitors), 2) downstream signaling (kinase inhibitors) and 3) the upstream pathway (kinase inhibitor and monoclonal antibody) [12, 13] . Perillyl alcohol (POH) a dietary monoterpene found in essential oils of citrus peel, mints, celery seeds and several vegetables, presents in vitro and in vivo inhibitory effect upon cell cycle and survival pathways leading to apoptosis of transformed cells [14] . The chemopreventive activity of POH is partly related to inhibition of FTase enzyme and oxidative stress responses which ultimately halt tumor cell proliferation, and could be a useful therapeutic approach for patients with recurrent malignant glioma [15] [16] [17] .
The efficacy of any anti-cancer drug greatly depends that therapeutic concentrations reaches the tumor site, a situation that is difficult to overcome concerning brain tumors due to the presence of the blood-brain barrier that restrains free drug access into the central nervous system [18] . However, the intranasal route provides a practical, noninvasive method for transportation of lipophilic and apolar drugs straight to the central nervous system [19] . In this context, we have been conducting a Phase I/II clinical trial to assess the efficacy of the monoterpene POH administered by intranasal route in patients with recurrent GBM [20, 21] . This report aimed to document a case of recurrent GBM successfully treated with intranasal perillyl alcohol administration as single chemotherapeutic agent without any evidence of adverse effects for more than 5 years.
Case Presentation
The present study was approved by the University Hos- A 37-years-old twelve-months pregnant white woman with no significant past medical record and without family history of brain tumor or neurological disorder had a seizure while sleeping at age 28 in October 1999. A brain magnetic resonance (MRI) scan revealed a regular space-occupying lesion in the right temporal lobe that enhanced with gadolinium. Patient underwent a right temporal craniotomy with radical resection of the primary brain tumor which was also confirmed by MRI scan performed after surgery. Histological analyzes confirmed diagnosis of grade II astrocytoma. (Figures 1(a), (c) ) and characteristic histological alterations (necrosis, palisade cells, marked nuclear atypia and abnormal mitoses) characteristic of glioblastoma multiforme (Figure 2) .
Patient started additional cycle of temozolomide schedule but treatment was withdrawn in February 2005 because patient was refractory to treatment, and presented clinical adverse effects (nausea, vomiting, thrombocytopenia) with resonance image scan showing no reduction of the tumoral lesion. The patient was then considered out of therapeutic possibilities and indicated for supportive (palliative) treatment. At this moment (August 2008), the patient was accepted to join Phase I/II protocol of intranasal administration of 268 mg POH daily as single chemotherapy. Intranasal POH treatment caused marked reduction of tumor size (Figures 1(b), (d) cystic lesions in the right cerebral hemisphere with area of contrast impregnation, loss of volumetric white matter, compensatory dilation of lateral and third ventricles with deviation of midline structures to the right side secondary to retractable effect. It was also observed reduced volume in the right cerebral peduncle secondary to Wallerian degeneration (Figures 3(a), (b) ). Patient remained in good health for more than 5 years (October 2010) and fully recovered from clinical neurological symptoms. Recent data from clinical laboratory analysis (Table 1) showed parameters within normal range values and also normal chest X-ray performed regularly at six monthly intervals since 2003 (data not shown). At the present moment patient still takes antiseizure medications but no steroidal drugs, and during all this period (more than 5 years) it was not observed any sign of toxicity or adverse effects caused by POH intranasal treatment.
Discussion
Only a subset of patients with newly diagnosed GBM exhibits a response to standard therapy [22] . Clinical failure of treatment for brain tumors may be largely attributed to a lack of appropriate brain drug delivery in a safe and effective manner [18] . Herein we report a case of a patient with recurrent GBM that had been successfully treated with intranasal administration of the monoterpene POH as single agent for more than five years without any side effects. As a result of intranasal POH treatment, the patient showed regression of tumor size and had a good prognosis despite dismal prognosis reported for GBM recurrence, that often presents a median survival of 3 -6 months [1] .
A prospective study carried out by our group [20] indicates that patients with recurrent secondary GBM have longer overall survival than those with primary recurrent GBM. Primary and secondary GBMs constitute distinct disease subtypes developing through different genetic alterations and signaling pathways [7, 22] . Recently a microarray data predictive of poor patient outcome refractory to standard treatment, associate a panel of gene expression with mesenchymal differentiation and angiogenesis activation [22] . The EGFR-mediated signal transduction results in activation of a number of downstream pathways including p21-Ras-MAPK that inhibits apoptosis but activates proliferation and angiogenesis. Considering that activation of p21-Ras signal transduction is a characteristic event of a highly proliferative glioma, strategies inhibiting Ras prenylation could be used as an efficient adjuvant therapy. Data showing that POH inhibits prenylation of Ras and other proteins in many cell types [23] support the view that POH could also be effective against glioma cells. Indeed data from our group showed that POH induced apoptosis, inhibited angiogenesis and migration of glioma cell lines and from human tumor explants [17] . Likewise clinical studies showed that the intranasal formulation of POH prolonged overall survival and reduced tumor size of recurrent GBM [20, 24, 25] . We herein report a case of a patient with recurrent GBM that presents stable disease, without any clinical evidence of recurrence for more than 5 years of treatment exclusively with daily administration by intranasal route of 268 mg POH, a Ras inhibitor. This therapeutic strategy is a noninvasive approach that can reduce systemic side effects, because overcome the need for hepatic processing often necessary for activation of most drugs administered by oral or intravenous route [26, 27] . It is conceivable that a lipophilic agent like POH administered by intranasal route might also be used as a carrier transporting anti-neoplastic drugs straight into the central nervous system. The present study shows an efficient response of recurrent glioblastoma to intranasal administration of POH, a safe and well-tolerated therapeutic regimen with clear antitumor activity.
